Companies › Actio Biosciences
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ABS-1230 KCNT1 inhibitor | Ion channels | Phase 2 | KCNT1-Related Epilepsy | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07156201 | ABS-1230 | Phase 1 | KCNT1-Related Epilepsy | Neurology | Dec 2026 |
| NCT07600736 | ABS-1230 | Phase 2 | KCNT1-Related Epilepsy | Neurology | Jan 2027 |
Biossil Xenon Pharmaceuticals Dasher Neuroscience ThromBio Appello Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.